#USA #Houston #Echolight #Bone Density #REMS technology

Echolight to Demonstrate Radiation-Free Bone Density Scanning at RSNA 2025

Echolight, a pioneer in bone densitometry solutions, is gearing up to showcase its groundbreaking REMS (Radiofrequency Echographic Multi-Spectrometry) technology at the upcoming Radiological Society of North America (RSNA) Congress in 2025. This event will spotlight the innovative ability of Echolight's system to measure bone density and microarchitecture without the radiation associated with traditional X-ray scans. Instead, the system utilizes an easy-to-perform ultrasound method focusing on axial anatomical sites such as the spine and femur.

Advantages of Echolight's Technology

The REMS technology represents a significant leap in diagnostics, primarily through its radiation-free approach, making it both safe and practical for repeated use over time. This characteristic is especially important for monitoring patients with specific needs, including pregnant women, pediatric populations, and oncology patients. One key feature of this innovative method is its ability to automatically exclude artifacts, which are often present in other densitometry techniques. This ensures that the diagnostic assessments produced are highly reliable.

Furthermore, the examinations do not require special lead-lined rooms, allowing for greater flexibility in patient positioning and comfort during scans. The ability to conduct these procedures with minimal setup enhances accessibility for both healthcare providers and patients alike.

Recent Studies Supporting REMS

Echolight's technology is backed by strong clinical evidence, with two recent studies validating the effectiveness of the REMS approach. The first study, highlighted by Mike Yuja, Chief Commercial Officer of Echolight USA, marks a turning point for clinical acceptance of the REMS technology worldwide. The publication outlines established practice parameters reinforced by international experts, solidifying the role of REMS as a trusted and economical solution for assessing bone health across diverse patient demographics. Yuja emphasizes the clinical relevance of the results, noting that with the integration of REMS into routine practices, clinicians can depend on its accuracy for enhanced diagnosis and better monitoring of bone health.

The second pivotal study evaluates the potential of REMS technology in monitoring bone health among pregnant women. Traditionally, assessing bone changes related to fetal calcium demands has been hampered by invasive methods. The prospective study involved 164 healthy pregnant women and demonstrated significant findings — particularly the marked reduction in bone mineral density (BMD) during the second and third trimesters and its correlation to supplement intake. These insights affirm REMS as a powerful tool for dynamic assessment of bone changes throughout pregnancy, illustrating its immense clinical utility in managing maternal and fetal health.

The Future for Echolight and REMS

Visitors to the Echolight booth (#3165) during RSNA 2025 will have the opportunity to discuss these findings and gain further insights into how this innovative technology can be integrated into clinical practice. Echolight continues to advance its vision by offering a portable solution that evaluates bone density at both the lumbar vertebrae and femoral neck. It provides critical diagnostic parameters including BMD, T-scores, Z-scores, and even a fragility score, which assesses the imminent risk of fractures over a five-year period.

Founded in Italy and with a head office in Lecce, Echolight has been making waves in the medical field since opening its U.S. offices in 2020. It has grown its global distribution network to over 40 partners and has gained the trust of hundreds of satisfied clients adopting the innovative REMS technology for their patient assessments. As a spin-off of the Italian National Research Council, Echolight is committed to introducing cutting-edge medical solutions, validated by numerous quality certifications worldwide including ISO standards and FDA clearance.

Conclusion

Echolight’s participation at RSNA 2025 not only showcases its technological advancements but also emphasizes its commitment to improving patient outcomes in bone health assessment. The radiation-free, reliable, and flexible nature of the REMS technology has the potential to revolutionize how healthcare providers monitor and manage bone health across all patient populations. With the backing of significant clinical data and growing recognition in the medical community, Echolight is set to shape the future of bone density diagnostics.